ICM
CNCE

ISZO Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

ISZO Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$2.61M Buy
+152,988
New +$1.83M 4.54% 8

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ISZO Capital Management's CNCE Position: Q1 2017 in Review

ISZO Capital Management opened a new position in Concert Pharmaceuticals, Inc. (CNCE) in Q1 2017: 152,988 shares worth $2.61M. The stake represents 4.54% of the portfolio and ranks #8 among its holdings.

85 funds tracked by Wall St. Rank hold CNCE as of Q1 2017.

  • ISZO Capital Management held 152,988 shares of Concert Pharmaceuticals, Inc. worth $2.61M as of Q1 2017.
  • Concert Pharmaceuticals, Inc. was a new ISZO Capital Management position in Q1 2017.
  • Concert Pharmaceuticals, Inc. made up 4.54% of ISZO Capital Management's portfolio in Q1 2017, its #8 holding.
  • 85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2017.

Based on ISZO Capital Management's 13F filing for Q1 2017, filed 15 May 2017.